The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine

Cancer Research

Volumn 60, Issue 21, 2000, Pages 6080-6088

  Ostruszka, L J ^a   Shewach, D S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DRUG METABOLITE; GEMCITABINE; HYDROXYUREA; PROTEIN P53; RADIOSENSITIZING AGENT; RIBONUCLEOTIDE REDUCTASE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL METABOLISM; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG METABOLISM; GLIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; RADIOSENSITIZATION;

ADENOSINE TRIPHOSPHATE; APOPTOSIS; BROMODEOXYURIDINE; CELL CYCLE; DEOXYADENINE NUCLEOTIDES; DEOXYCYTIDINE; GLIOBLASTOMA; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034326813     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Gemcitabine. Current status of Phase I and II trials
2. A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
3. An investigational new drug treatment program for patients with gemcitabine-results for over 3000 patients with pancreatic carcinoma
4. Maximum-tolerated dose defined for single-agent gemcitabine: A Phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer
5. Single-agent activity of weekly gemcitabine in advanced non-small lung cancer: A Phase II study
6. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines
7. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine
8. Nucleotide specificity of human deoxycytidine kinase
9. Effect of a template-located 2',2'-difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klenow (3'-5' exonuclease-) fragment
10. Action of 2',2'-difluorodeoxycytidine on DNA synthesis
11. Molecular effects of 2',2'-difluorodeoxycytidine (gemcitabine) on DNA replication in intact HL-60 cells
12. 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
13. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine
14. 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase
15. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: A mechanism of self-potentiation
16. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2', 2'-difluorodeoxycytidine
17. Gemcitabine. Preclinical pharmacology and mechanisms of action
18. The combined effect of hydroxyurea and X-rays on Chinese hamster cells in vitro
19. The effects of incorporation of 5-halogenated deoxyuridines into the DNA of eukaryotic cells
20. Decrease in TTP pools mediated by 5-bromo-2'-deoxyuridine exposure in a human glioblastoma cell line
21. Effect of 2',2'-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro
22. Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells
23. Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine
24. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model
25. Enhancement of tumor radioresponse in vivo by gemcitabine
26. Maximizing therapeutic gain with gemcitabine and fractionated radiation
27. Phase I trial of radiation (RT) concurrent with low-dose gemcitabine (GEM) for head and neck cancer. High mucosal and pharyngeal toxicity
28. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
29. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy
30. Modification of radiotherapy by radiosensitizers and cancer chemotherapy agents. I. Radiosensitizers
31. X-ray sensitization by halopyrimidines
32. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the northern California oncology group (NCOG) and radiation therapy oncology group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma
33. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (gemcitabine)
34. Bromodeoxyuridine-mediated radiosensitization in human glioma: The effect of concentration, duration, and fluoropyrimidine modulation
35. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
36. Analysis of the p53 gene and its expression in human glioblastoma cells
37. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis
38. Molecular changes during the genesis of human gliomas
39. Alterations of the TP53 gene in human gliomas
40. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: Comparison with conventional structural analyses
41. p53, The cellular gatekeeper for growth and division
42. Gemcitabine and radiosensitization in two glioblastoma cell lines
43. Mean inactivation dose: A useful concept for intercomparison of human cell survival curves
44. Quantitation of deoxyribonucleoside 5'-triphosphates by a sequential boronate and anion-exchange high pressure liquid chromatography procedure
45. Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): Critical factors that affect the amount of fluorescence and the shape of the BrdUrd/DNA histogram
46. Mechanism of radiosensitization by halogenated pyrimidines: Effect of BrdU on radiation induction of DNA and chromosome damage and its correlation with cell killing
47. Signaling to p53: Breaking the mdm2-p53 circuit
48. Mdm-2: 'Big Brother' of p53
49. Cytokinetic properties of asynchronous and 1-β-D-arabinofuranosylcytosine perturbed murine tumors measured by simultaneous bromodeoxyuridine/DNA analyses
50. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event
51. The p53 network
52. Gemcitabine cytotoxicity of human malignant glioma cells: Modulation by antioxidants, BCL-2 and dexamethasone
53. Gemcitabine and radiosensitization in human tumor cells
54. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis
55. DNA damage and p53-mediated cell cycle arrest: A reevaluation
56. p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma
57. Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells
58. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
59. p53 Mutations increase resistance to ionizing radiation
60. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines
61. Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro
62. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines
63. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT-29 colon cancer cells
64. Apoptosis in astrocytomas with different grades of malignancy
65. Radiation-induced apoptosis: Relevance to radiotherapy